Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovorafenib, Plozalizumab, or Vedolizumab with Checkpoint Inhibitors in Advanced Melanoma
NCT02723006Phase 1Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- May 2018
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of tovorafenib, plozalizumab and vedolizumab in melanoma (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Dose Limiting Toxicities at 7 weeks. Started Jun 2016; status: terminated.
02
Drugs
tovorafenibplozalizumabvedolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02723006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723006.